Product Description
Difluprednate ophthalmic is used to treat eye swelling and pain after eye surgery. Difluprednate ophthalmic is in a class of medications called corticosteroids. It works by stopping the release of certain natural substances that cause swelling and pain. (Sourced from: https://medlineplus.gov/druginfo/meds/a609025.html)
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Ocular, Ophthalmic
FDA Designation: *
Approval Status: Approved
Approved Countries: Bangladesh | Canada | Colombia | Dominican Republic | Ecuador | Egypt | France | India | Italy | Korea | Mexico | Peru | Turkey | United Arab Emirates | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/18/2025 |
News Article |
UPSHER-SMITH ADDS DIFLUPREDNATE OPHTHALMIC EMULSION TO ITS GENERICS PORTFOLIO |
|
07/23/2025 |
News Article |
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME) |
|
11/18/2024 |
News Article |
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements |
|
08/19/2024 |
News Article |
Visiox Pharmaceuticals, Inc. Announces Transformative Merger with Ocuvex Therpeutics, Inc. |